

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**四川科倫博泰生物醫藥股份有限公司**  
*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 6990)**

**VOLUNTARY ANNOUNCEMENT**  
**UPDATE ON COLLABORATION WITH MERCK SHARP & DOHME LLC**  
**FOR CORE PRODUCT SKB264 (MK-2870)**

The board (the “**Board**”) of directors (“**Directors**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”, and together with its subsidiaries, the “**Group**”) would like to update its shareholders and potential investors on the Group’s collaboration with Merck Sharp & Dohme LLC (together with its affiliates, “**MSD**”) for the Company’s core product SKB264 (also known as MK-2870).

In May 2022, the Company licensed exclusive rights to MSD to develop, manufacture and commercialize SKB264 (MK-2870) in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan) (the “**License and Collaboration Agreement**”).

As of the date of this announcement, MSD has announced that it initiated three pivotal phase 3 clinical trials, evaluating SKB264 (MK-2870) as a monotherapy for the treatment of previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations or other genomic alterations, as a monotherapy for the treatment of endometrial carcinoma (EC) previously treated with platinum-based chemotherapy and immunotherapy, and in combination with pembrolizumab for metastatic NSCLC expressing programmed death ligand 1 (PD-L1) greater than or equal to 50 percent.

Pursuant to the License and Collaboration Agreement and a written confirmation from MSD, the aforementioned clinical trials for NSCLC and EC have triggered payment of the relevant clinical milestones in the aggregate amount of US\$75.0 million. The Company has received a partial payment from MSD and expects to receive the balance in the near future.

## **RISK WARNING**

**SKB264 (MK-2870) MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, February 23, 2024

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*